References
- Campbell DJ, Nussberger J, Stowasser M, et al. (2009). Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 55:867–77
- Dadoun R. (2000). Implementing preanalytical automation. The right volume, the right workflow. MLO Med Lab Obs 32:32–6
- de Rita O, Hackam DG, Spence JD. (2012). Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 28:706--11
- Funder JW, Carey RM, Fardella C, et al. (2008). Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266–81
- Gruson D, Bodovitz S. (2010). Rapid emergence of multimarker strategies in laboratory medicine. Biomarkers 15:289–96
- Gruson D, Maisin D, Lison P, et al. (2011). Two-site automated chemiluminescent assay for measurement of immunoreactive renin. Biomarkers 16:605--9
- Hawker CD, Garr SB, Hamilton LT, et al. (2002a). Automated transport and sorting system in a large reference laboratory: part 1. Evaluation of needs and alternatives and development of a plan. Clin Chem 48:1751–60
- Hawker CD, Roberts WL, Garr SB, et al. (2002b). Automated transport and sorting system in a large reference laboratory: part 2. Implementation of the system and performance measures over three years. Clin Chem 48:1761–7
- Hinchliffe E, Carter S, Owen LJ, Keevil BG. (2013). Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 15:913--14
- Ma TK, Kam KK, Yan BP, Lam YY. (2010). Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160:1273–92
- Mignano A, Pitruzzella V, Arnone G, et al. (2013). Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. J Cardiovasc Med (Hagerstown). [Epub ahead of print]. doi: 10.2459/JCM.0b013e328364129c
- Mulatero P, Stowasser M, Loh KC, et al. (2004). Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89:1045–50
- Olivieri O, Ciacciarelli A, Signorelli D, et al. (2004). Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 89:4221–6
- Palmer BR, Pilbrow AP, Frampton CM, et al. (2008). Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 29:2489–96
- Perschel FH, Schemer R, Seiler L, et al. (2004). Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 50:1650–5
- Pitt B. (2012). Plasma aldosterone levels in patients with coronary artery disease without heart failure or myocardial infarction: implications for pathophsiology, prognosis, and therapy. Eur Heart J 33:162–4
- Savard S, Amar L, Plouin PF, Steichen O. (2013). Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62:331--6
- Schirpenbach C, Seiler L, Maser-Gluth C, et al. (2006). Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 52:1749–55
- Stowasser M, Gordon RD. (2013). The renaissance of primary aldosteronism: what has it taught us? Heart Lung Circ 22:412--20
- Szymanski MK, Damman K, van Veldhuisen DJ, et al. (2011). Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. Am Heart J 162:487–93
- Volpe M, Battistoni A, Chin D, et al. (2012). Renin as a biomarker of cardiovascular disease in clinical practice. Nutr Metab Cardiovasc Dis 22:312–17
- White PC. (2003). Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 88:2376–83